Cargando…

Cerebrospinal Fluid MicroRNA Signatures as Diagnostic Biomarkers in Brain Tumors

Central nervous system (CNS) malignancies include primary tumors that originate within the CNS as well as secondary tumors that develop as a result of metastatic spread. Circulating microRNAs (miRNAs) were found in almost all human body fluids including cerebrospinal fluid (CSF), and they seem to be...

Descripción completa

Detalles Bibliográficos
Autores principales: Kopkova, Alena, Sana, Jiri, Machackova, Tana, Vecera, Marek, Radova, Lenka, Trachtova, Karolina, Vybihal, Vaclav, Smrcka, Martin, Kazda, Tomas, Slaby, Ondrej, Fadrus, Pavel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826583/
https://www.ncbi.nlm.nih.gov/pubmed/31614872
http://dx.doi.org/10.3390/cancers11101546
_version_ 1783465122045362176
author Kopkova, Alena
Sana, Jiri
Machackova, Tana
Vecera, Marek
Radova, Lenka
Trachtova, Karolina
Vybihal, Vaclav
Smrcka, Martin
Kazda, Tomas
Slaby, Ondrej
Fadrus, Pavel
author_facet Kopkova, Alena
Sana, Jiri
Machackova, Tana
Vecera, Marek
Radova, Lenka
Trachtova, Karolina
Vybihal, Vaclav
Smrcka, Martin
Kazda, Tomas
Slaby, Ondrej
Fadrus, Pavel
author_sort Kopkova, Alena
collection PubMed
description Central nervous system (CNS) malignancies include primary tumors that originate within the CNS as well as secondary tumors that develop as a result of metastatic spread. Circulating microRNAs (miRNAs) were found in almost all human body fluids including cerebrospinal fluid (CSF), and they seem to be highly stable and resistant to even extreme conditions. The overall aim of our study was to identify specific CSF miRNA patterns that could differentiate among brain tumors. These new biomarkers could potentially aid borderline or uncertain imaging results onto diagnosis of CNS malignancies, avoiding most invasive procedures such as stereotactic biopsy or biopsy. In total, 175 brain tumor patients (glioblastomas, low-grade gliomas, meningiomas and brain metastases), and 40 non-tumor patients with hydrocephalus as controls were included in this prospective monocentric study. Firstly, we performed high-throughput miRNA profiling (Illumina small RNA sequencing) on a discovery cohort of 70 patients and 19 controls and identified specific miRNA signatures of all brain tumor types tested. Secondly, validation of 9 candidate miRNAs was carried out on an independent cohort of 105 brain tumor patients and 21 controls using qRT-PCR. Based on the successful results of validation and various combination patterns of only 5 miRNA levels (miR-30e, miR-140, let-7b, mR-10a and miR-21-3p) we proposed CSF-diagnostic scores for each tumor type which enabled to distinguish them from healthy donors and other tumor types tested. In addition to this primary diagnostic tool, we described the prognostic potential of the combination of miR-10b and miR-196b levels in CSF of glioblastoma patients. In conclusion, we performed the largest study so far focused on CSF miRNA profiling in patients with brain tumors, and we believe that this new class of biomarkers have a strong potential as a diagnostic and prognostic tool in these patients.
format Online
Article
Text
id pubmed-6826583
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-68265832019-11-18 Cerebrospinal Fluid MicroRNA Signatures as Diagnostic Biomarkers in Brain Tumors Kopkova, Alena Sana, Jiri Machackova, Tana Vecera, Marek Radova, Lenka Trachtova, Karolina Vybihal, Vaclav Smrcka, Martin Kazda, Tomas Slaby, Ondrej Fadrus, Pavel Cancers (Basel) Article Central nervous system (CNS) malignancies include primary tumors that originate within the CNS as well as secondary tumors that develop as a result of metastatic spread. Circulating microRNAs (miRNAs) were found in almost all human body fluids including cerebrospinal fluid (CSF), and they seem to be highly stable and resistant to even extreme conditions. The overall aim of our study was to identify specific CSF miRNA patterns that could differentiate among brain tumors. These new biomarkers could potentially aid borderline or uncertain imaging results onto diagnosis of CNS malignancies, avoiding most invasive procedures such as stereotactic biopsy or biopsy. In total, 175 brain tumor patients (glioblastomas, low-grade gliomas, meningiomas and brain metastases), and 40 non-tumor patients with hydrocephalus as controls were included in this prospective monocentric study. Firstly, we performed high-throughput miRNA profiling (Illumina small RNA sequencing) on a discovery cohort of 70 patients and 19 controls and identified specific miRNA signatures of all brain tumor types tested. Secondly, validation of 9 candidate miRNAs was carried out on an independent cohort of 105 brain tumor patients and 21 controls using qRT-PCR. Based on the successful results of validation and various combination patterns of only 5 miRNA levels (miR-30e, miR-140, let-7b, mR-10a and miR-21-3p) we proposed CSF-diagnostic scores for each tumor type which enabled to distinguish them from healthy donors and other tumor types tested. In addition to this primary diagnostic tool, we described the prognostic potential of the combination of miR-10b and miR-196b levels in CSF of glioblastoma patients. In conclusion, we performed the largest study so far focused on CSF miRNA profiling in patients with brain tumors, and we believe that this new class of biomarkers have a strong potential as a diagnostic and prognostic tool in these patients. MDPI 2019-10-12 /pmc/articles/PMC6826583/ /pubmed/31614872 http://dx.doi.org/10.3390/cancers11101546 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kopkova, Alena
Sana, Jiri
Machackova, Tana
Vecera, Marek
Radova, Lenka
Trachtova, Karolina
Vybihal, Vaclav
Smrcka, Martin
Kazda, Tomas
Slaby, Ondrej
Fadrus, Pavel
Cerebrospinal Fluid MicroRNA Signatures as Diagnostic Biomarkers in Brain Tumors
title Cerebrospinal Fluid MicroRNA Signatures as Diagnostic Biomarkers in Brain Tumors
title_full Cerebrospinal Fluid MicroRNA Signatures as Diagnostic Biomarkers in Brain Tumors
title_fullStr Cerebrospinal Fluid MicroRNA Signatures as Diagnostic Biomarkers in Brain Tumors
title_full_unstemmed Cerebrospinal Fluid MicroRNA Signatures as Diagnostic Biomarkers in Brain Tumors
title_short Cerebrospinal Fluid MicroRNA Signatures as Diagnostic Biomarkers in Brain Tumors
title_sort cerebrospinal fluid microrna signatures as diagnostic biomarkers in brain tumors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826583/
https://www.ncbi.nlm.nih.gov/pubmed/31614872
http://dx.doi.org/10.3390/cancers11101546
work_keys_str_mv AT kopkovaalena cerebrospinalfluidmicrornasignaturesasdiagnosticbiomarkersinbraintumors
AT sanajiri cerebrospinalfluidmicrornasignaturesasdiagnosticbiomarkersinbraintumors
AT machackovatana cerebrospinalfluidmicrornasignaturesasdiagnosticbiomarkersinbraintumors
AT veceramarek cerebrospinalfluidmicrornasignaturesasdiagnosticbiomarkersinbraintumors
AT radovalenka cerebrospinalfluidmicrornasignaturesasdiagnosticbiomarkersinbraintumors
AT trachtovakarolina cerebrospinalfluidmicrornasignaturesasdiagnosticbiomarkersinbraintumors
AT vybihalvaclav cerebrospinalfluidmicrornasignaturesasdiagnosticbiomarkersinbraintumors
AT smrckamartin cerebrospinalfluidmicrornasignaturesasdiagnosticbiomarkersinbraintumors
AT kazdatomas cerebrospinalfluidmicrornasignaturesasdiagnosticbiomarkersinbraintumors
AT slabyondrej cerebrospinalfluidmicrornasignaturesasdiagnosticbiomarkersinbraintumors
AT fadruspavel cerebrospinalfluidmicrornasignaturesasdiagnosticbiomarkersinbraintumors